Non-small cell lung cancer: the role of cytoprotection in treating therapy-related toxicity.
Concurrent radiochemotherapy improves outcomes in patients with stage III non-small cell lung cancer but produces greater toxicity, especially esophagitis and pneumonitis. Preliminary evidence suggests that cytoprotection might decrease the incidence and severity of therapy-related toxicity in these patients. In radiation-related pneumonitis, the protective effect of amifostine appears to be partly the result of a reduction in the accumulation of macrophages and a decrease in plasma and tissue tumor growth factor-beta levels.